Please enter a search term.

  • English German
  • Investors
  • News
  • Presentations
  • Contact Us
  • electroCore logo

  • English German
  • Home
  • About Us
    • Leadership
    • Our History
  • nVNS Therapy
  • Products
  • Medical Affairs
    • Multimedia
    • Publications
  • Investors
    • News Releases
    • Events and Presentations
    • Corporate Governance
    • SEC Filings
    • Investor Services
  • News
  • Contact Us
POSTED BY
December 14, 2017
Share this article Print this article
Save article as PDF
GO BACK TO ARTICLES

National Institute of Health Research (NIHR) publication reinforces potential role of gammaCore in helping UK patients manage medically unexplained symptoms (MUS)

electroCore welcomes the recent NIHR technology alert on gammaCore, which profiles the CE-marked device’s role in helping patients in the UK manage long-term neurological conditions such as migraine and medically unexplained symptoms. The alert, which is designed to notify clinicians and those involved in the commissioning of healthcare products or services of the availability of new technologies, highlights the potential for gammaCore to enhance the quality of life for people with long-term conditions, thereby aligning with this domain within the NHS Outcomes Framework.

Based upon independent research funded by the NIHR, and published within the NIHR’s Horizon Scanning Research and Intelligence Centre (HSRIC), this alert bolsters the Company’s belief in the potential of gammaCore to help alleviate some of the unique pressures that exist within the UK’s healthcare system. By empowering patients to safely and effectively self-manage their medically unexplained symptoms at home, it is anticipated that usage of the device will help to reduce the workload demand currently placed on GPs and the wider health and social care system.

gammaCore received its first CE mark in 2011, and a positive review from the Interventional Procedures Advisory Committee of the National Institute for Health and Care Excellence (NICE), on its role in the prevention and acute treatment of migraine and cluster headache in April 2016.

The NIHR technology alert can be accessed via the following link: http://www.hsric.nihr.ac.uk/topics/gammacore-for-the-treatment-of-medically-unexplained-symptoms/

electrocore
  • Compliance
  • Terms of Use
  • Privacy Policy
  • Quality Policy
  • Patents
  • Terms and Conditions
  • Accessibility Statement
  • electroCore Apparel Shop
©2025 electroCore, Inc. All rights reserved. electroCore, the electroCore logo, gammaCore, the gammaCore logo, gammaCore Sapphire, the gammaCore Sapphire logo, Truvaga, and the Truvaga logo, TAC-STIM, and the TAC-STIM logo are trademarks of electroCore, Inc. EPM-00019 Rev 19 Rel: 10/2024

electroCore is committed to the safety and care of our patients, providers, and employees during the COVID-19 pandemic. We have implemented several operational enhancements, research initiatives, and virtual capabilities to ensure patients who depend on us have uninterrupted access to gammaCoreTM (non-invasive vagus nerve stimulator). To learn more about our efforts please call (888) 903-CORE.

×

You are leaving electrocore.com


PROCEED

Cancel

×

You are leaving electrocore.com


PROCEED

Cancel

By clicking “Accept” you are agreeing to eletroCore to place cookies on your browser to gather web statistics that help us improve our site experience. Please read our Privacy Policy for more information on the types of cookies we use.

Accept More Info